Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

J. Slamon, Dennis; Neven, Patrick; Chia, Stephen; A. Fasching, Peter; De Laurentiis, Michelino; Im, Seock-Ah; Petrakova, Katarina; V. Bianchi, Giulia; J. Esteva, Francisco; Martín, Miguel; Nusch, Arnd; S. Sonke, Gabe; De la Cruz-Merino, Luis; Thaddeus Beck, J.; Pivot, Xavier; Sondhi, Manu; Wang, Yingbo; Chakravartty, Arunava; Rodriguez-Lorenc, Karen; Taran, Tetiana; Jerusalem, Guy

doi:10.1056/nejmoa1911149

Public

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Published in New England Journal of Medicine • Feb 6, 2020

Authors:

Dennis J. Slamon

Patrick Neven

Stephen Chia

Abstract

BACKGROUND: In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!